Yahoo Web Search

Search results

1. • 

     The 32 greatest Tom Cruise movies

     Games Radar· 6 days ago

     For decades, the name Tom Cruise has been synonymous with Hollywood movies. Raised in near poverty under an abusive father, Cruise took up acting in high...

2. • Live from ASCO 2024 | Ascentage Pharma Releases Updated Data of FAK/ALK/ROS1 Inhibitor APG-2449 in...

     Benzinga· 3 days ago

     SUZHOU, China, and ROCKVILLE, Md., June 1, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related

3. • Adaptimmune to Present Data from Planned Interim Analysis of Pivotal IGNYTE-ESO Trial with Lete-cel...

     Digital Journal· 1 day ago

     Overall response rate of 40% consistent across sarcoma indications; median duration of response ~11 months with patients still in response at time of analysisInterim analysis data reinforces ...

4. • Small Business - Shelby County Reporter | Shelby County Reporter

     The Shelby County Reporter· 3 days ago

     Live from ASCO 2024 | Ascentage Pharma Releases Updated Data of FAK/ALK/ROS1 Inhibitor APG-2449 in Patients with NSCLC PR Newswire SUZHOU, China, and ROCKVILLE, Md., June 1, 2024 SUZHOU, China ...

5. • 

     Journalists Talk Cost of Weight Loss Drugs and Lack of Obesity Doctors to Manage Their Use

     North Denver News· 4 days ago

     This week’s good news report. KFF Health News senior correspondent Renuka Rayasam discussed weight...

6. • Small Business - Shelby County Reporter | Shelby County Reporter

     The Shelby County Reporter· 16 hours ago

     Live from ASCO 2024 | Updated Data of Bcl-2 Inhibitor Lisaftoclax Combined with Azacitidine in Patients with AML Demonstrate Promising Efficacy and Manageable Safety PR Newswire SUZHOU, China ...

7. • Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1...

     Morningstar· 3 days ago

     Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO ...

8. • Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves...

     Clearfield Progress· 5 days ago

     Akeso, Inc. (HKEX: 9926.HK) ("Akeso," "we," or the "Company") today announced that the Phase III clinical trial, HARMONi-2 or AK112-303, met its primary endpoint of progression-free survival ...

9. • Small Business - Cordele Dispatch | Cordele Dispatch

     Cordele Dispatch· 2 days ago

     Innovent Announces Taletrectinib（ROS1 Inhibitor）Updated Data from Pivotal Phase 2 TRUST-I Study of are Published in the JCO and Orally Presentedat 2024 ASCO Annual Meeting PR Newswire SAN FRANCISCO and SUZHOU, China, June 2, 2024 SAN FRANCISCO and